Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Libo Bio

Explore full profile

AI-powered small molecule drugs targeting RNA

ChinaFounded 2022Biotech & Life Sciences
Valuation $50–100M Last recorded · 2025
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Libo Bio and the history behind them.

About Libo Bio

Ribopeutic develops small molecule drugs targeting RNA to treat cancer, rare diseases, and viral infections. The company utilizes a proprietary, AI-driven, wet-dry closed-loop platform to discover novel RNA targets suitable for drug development. This approach aims to provide innovative drugs to address unmet clinical needs in its target therapeutic areas.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2022
Headquarters
China
Open positions
None listed
Dealroom signal
17.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Oncology, Precision Medicine, RNA, Disease, AI Drug Discovery, Rare Diseases, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b
Links
Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom
News
News Libo Bio raises $15M Series A for RNA-targeting small molecules Oct 30, 2026

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEED✓Equity / VC Aug 2025 $14M $55M Yuansheng Venture Capital · Guangzhou Chengxin Venture Capital · Tasly Capital · Pan-Lin Asset Management ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
LajollalabsHigh-Throughput Screening Technology for Drug Discovery San Diego, United States Operational 6 — —
Tres AlchemixAI-powered drug discovery platform using quantum chemical calculations Fukuoka, Japan Operational
Ridge BiotechnologiesAI-enabled platform for precision enzyme and drug design Palo Alto, United States Operational
Therna BiosciencesAI-powered platform designing programmable RNA medicines San Carlos, United States Operational
Stipple BioUnlocking cellular profiling and target discovery with epitope resolution Cambridge, United States Operational
Reveal GenomicsDeveloping tests that harness the full potential of comprehensive genetic and clinical data for each patient Barcelona, Spain Operational
pear bioBiotechnology company that develops biomedical technologies for cancer treatment by testing patients' drug resistance London, United Kingdom Operational
One BiosciencesOperating a ‘discovery engine’ leveraging single-cell technologies to identify new therapeutics for difficult-to-treat diseases Paris, France Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

0 profiles shownExplore the complete relationship graph →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed4 investors entered at this stage

  • Tasly Capital
  • Pan-Lin Asset Management
  • Yuansheng Venture Capital
  • Guangzhou Chengxin Venture Capital

Talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Libo Bio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Libo Bio’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.